CG200745 PPA + gemcitabine + erlotinib

This is an investigational **combination drug regimen** composed of CG200745 PPA, gemcitabine, and erlotinib. - **CG200745 PPA** is a histone deacetylase (HDAC) inhibitor developed as an anti-cancer agent (specifically as a pan-HDAC inhibitor), although published studies on the exact PPA (pharmaceutical product arrangement or possibly a prodrug/adjuvant or salt form) variant are limited. - **Gemcitabine** is a nucleoside analog used as a chemotherapeutic agent that inhibits DNA synthesis, primarily indicated for pancreatic, non-small cell lung, and other cancers. - **Erlotinib** is a small molecule epidermal growth factor receptor (EGFR, also called HER1) tyrosine kinase inhibitor used in the treatment of pancreatic and non-small cell lung cancers. The combination of gemcitabine and erlotinib is an established regimen for pancreatic cancer, improving survival modestly over gemcitabine alone[5][6][4]. The addition of an HDAC inhibitor such as CG200745 PPA is research-stage and potentially aimed at overcoming resistance or enhancing the efficacy of the chemotherapy and targeted therapy backbone.